SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
GSK plc (GLAXF) trades at a trailing P/E of 21.0, forward P/E of 12.3. Trailing earnings yield is 4.75%, forward earnings yield 8.14%. PEG 0.17 (Peter Lynch undervalued ≤1.0).
Criteria proven by this page:
- VALUE (75/100, Pass) — P/E is below market average (21.0); PEG ≤ 1.0 — Peter Lynch undervalued (0.17); earnings yield beats bond yields (4.75%).
- Forward P/E 12.3 (down from trailing 21.0) — analysts expect earnings to grow, which would improve the valuation.
- PEG Ratio 0.17 — below 1.0 suggests the stock is undervalued relative to its earnings growth rate (Peter Lynch criterion).
- Trailing Earnings Yield 4.75% — roughly competitive with bond yields (~4.3%), moderate risk-reward. Forward yield improves to 8.14% as earnings recover.
Overall SharesGrow Score: 70/100 with 4/7 criteria passed.
SharesGrow 7-Criteria Score
✓
VALUE
75/100
Price-to-Earnings & upside
Proven by this page
~
HEALTH
50/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — GLAXF
Valuation Multiples
P/E (TTM)21.0
Forward P/E12.3
PEG Ratio0.17
Forward PEG0.17
P/B Ratio0.00
P/S Ratio3.69
EV/EBITDA0.0
Per Share Data
EPS (TTM)$1.39
Forward EPS (Est.)$2.38
Book Value / Share$0.00
Revenue / Share$7.93
FCF / Share$0.00
Yields & Fair Value
Earnings Yield4.75%
Forward Earnings Yield8.14%
Dividend Yield0.00%
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2016 |
$0.23 |
$27.89B |
$912M |
3.3% |
| 2017 |
$0.39 |
$30.19B |
$1.53B |
5.1% |
| 2018 |
$0.91 |
$30.82B |
$3.62B |
11.8% |
| 2019 |
$1.16 |
$33.75B |
$4.65B |
13.8% |
| 2020 |
$1.43 |
$34.1B |
$5.75B |
16.9% |
| 2021 |
$1.35 |
$34.11B |
$4.39B |
12.9% |
| 2022 |
$3.66 |
$29.32B |
$14.96B |
51% |
| 2023 |
$1.20 |
$30.33B |
$4.93B |
16.2% |
| 2024 |
$0.62 |
$31.38B |
$2.58B |
8.2% |
| 2025 |
$1.39 |
$32.66B |
$5.72B |
17.5% |
